When planning to scale up for clinical production, many companies work with multiple CDMOs to ensure supply chain stability. This strategy can take time and focus away from the primary objective — preparing the drug for trials.
In building your new drug program, investors are betting on you to effectively manage development. Answering their questions well increases the likelihood of receiving support for your company’s vision.
How do you get to IND/IMPD faster without sacrificing quality and future commercialization goals? Our experts share a few considerations when thinking about accelerating and optimizing your early development process.